二甲双胍治疗不影响腹主动脉瘤破裂风险
基于丹麦全国登记数据的巢式病例对照研究,在糖尿病患者中评估长期使用二甲双胍与腹主动脉瘤破裂(RAAA)的关联。共识别362例RAAA病例,长期二甲双胍使用者占22.4%,对照组占28.8%。粗OR为0.74(95%CI 0.54-1.00),调整后OR为0.84(95%CI 0.61-1.17),无统计学意义。结论:二甲双胍不增加糖尿病患者RAAA风险。
要点
- 在糖尿病患者中,长期二甲双胍使用与RAAA风险无显著关联(调整OR 0.84,95%CI 0.61-1.17)。
- 粗分析显示可能保护效应(OR 0.74,95%CI 0.54-1.00),但调整后无统计学意义。
- 亚组分析结果与主分析无实质性偏离。
核心结论
- 二甲双胍使用不增加糖尿病患者腹主动脉瘤破裂的风险。
研究设计与样本
- 基于丹麦全国登记数据的巢式病例对照研究,源人群为丹麦所有糖尿病患者。
- 病例为源人群中以RAAA为主要诊断住院的个体,每个病例按年龄和性别匹配10个对照。
- 主要暴露为1995年1月至索引日期之间二甲双胍累计配药量达1000克。
主要发现
- 1998至2013年间共识别362例RAAA,其中83.7%为男性,中位年龄74岁。
- 病例组中长期二甲双胍使用者占22.4%,对照组占28.8%。
- 粗OR为0.74(95%CI 0.54-1.00),调整协变量后OR为0.84(95%CI 0.61-1.17)。
- 各亚组OR与主结果无实质性偏离。
临床怎么用
- 对于合并糖尿病的腹主动脉瘤患者,二甲双胍治疗无需因担心动脉瘤破裂风险而调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Diabetes counteracts formation and rupture of abdominal aortic aneurysms, possibly through arterial matrix accumulation. Use of metformin, on the other hand, reduces arterial accumulation of matrix molecules. Consequently, we hypothesized that metformin treatment may reverse the protective role of diabetes on the development and course of aneurysms, that is, that metformin would be associated with aneurysm rupture among individuals with diabetes. METHODS: Using nationwide Danish registry data, we performed a nested case-control study on the association between long-term use of metformin and ruptured abdominal aortic aneurysm (RAAA). The source population was defined as all individuals in Denmark with diabetes. Cases were all individuals within the source population who were hospitalized with a primary diagnosis of RAAA. For each case, 10 controls matched by age and sex were randomly selected from the source population by risk set sampling. The main exposure measure was a cumulative dispensing of 1000 g of metformin between January 1995 and the index date. RESULTS: We identified 362 cases of RAAA during 1998 to 2013, of which 83.7% occurred in men with a median age of 74 years. In total, 22.4% of the case population were long-term metformin users compared with 28.8% of the controls. We found a statistically nonsignificant protective effect of long-term metformin use toward RAAA with crude odds ratio (OR) of 0.74 (confidence interval, 0.54-1.00). When adjusted for covariates, OR increased to 0.84 (confidence interval, 0.61-1.17). None of the subgroups had ORs deviating substantially from the main result. CONCLUSIONS: Metformin use does not increase the risk of RAAA among individuals with diabetes.
引用
- Kristensen KL, Pottegård A, Hallas J, et al. Metformin treatment does not affect the risk of ruptured abdominal aortic aneurysms. J Vasc Surg. 2017. PMID: 28506478. doi:10.1016/j.jvs.2017.01.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。